BofA Upgrades Haemonetics to Buy Amid Conservative FY27 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: seekingalpha
- Rating Upgrade: Bank of America upgraded Haemonetics from Neutral to Buy, with analyst Travis Steed noting that while the company has issued a conservative outlook for fiscal 2027, there is likely upside as the year progresses.
- Financial Outlook: Haemonetics projects FY27 revenue between $1.387 billion and $1.427 billion, aligning closely with the FactSet consensus of $1.39 billion, indicating the company's stability and foresight in the market.
- Market Performance: Despite U.S. plasma collections growing in high single-digit percentages in Q4 FY26, the company's outlook suggests only 0% to 2% growth, reflecting a cautious market sentiment regarding its growth potential.
- Valuation Analysis: With a P/E ratio of 11x, Haemonetics trades below what analysts consider fair value, prompting Steed to raise his price target from $70 to $80, based on a 14x multiple for 2027E, highlighting its strong profitability and free cash flow.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HAE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 67.040
Low
74.00
Averages
88.86
High
99.00
Current: 67.040
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Q1 Earnings Review of Medical Devices Sector
- Sector Performance: The medical devices sector saw its seven tracked companies collectively exceed analysts' revenue expectations by 5.2% in Q1, demonstrating resilience despite pricing pressures and regulatory challenges.
- Haemonetics Strong Results: Haemonetics reported revenues of $346.4 million, up 4.8% year-on-year, exceeding analysts' expectations by 2.6%, with its stock rising 10.6% since the report, indicating strong market confidence in its performance.
- STAAR Surgical Rapid Growth: STAAR Surgical achieved revenues of $93.52 million, a remarkable 120% increase year-on-year, outperforming analysts' expectations by 20.8%, with its stock up 14.8%, reflecting its strong market position and growth potential.
- Inspire Medical Systems Struggles: Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year-on-year, exceeding expectations by 1.9%, but its full-year guidance missed expectations, leading to a 19.5% drop in stock price, highlighting market concerns about its future performance.
See More
BofA Upgrades Haemonetics to Buy Amid Conservative FY27 Outlook
- Rating Upgrade: Bank of America upgraded Haemonetics from Neutral to Buy, with analyst Travis Steed noting that while the company has issued a conservative outlook for fiscal 2027, there is likely upside as the year progresses.
- Financial Outlook: Haemonetics projects FY27 revenue between $1.387 billion and $1.427 billion, aligning closely with the FactSet consensus of $1.39 billion, indicating the company's stability and foresight in the market.
- Market Performance: Despite U.S. plasma collections growing in high single-digit percentages in Q4 FY26, the company's outlook suggests only 0% to 2% growth, reflecting a cautious market sentiment regarding its growth potential.
- Valuation Analysis: With a P/E ratio of 11x, Haemonetics trades below what analysts consider fair value, prompting Steed to raise his price target from $70 to $80, based on a 14x multiple for 2027E, highlighting its strong profitability and free cash flow.
See More
Haemonetics Q4 Fiscal 2026 Earnings Call Insights
- Revenue Growth: Haemonetics reported fourth-quarter revenue of $346 million for fiscal 2026, reflecting a 5% increase year-over-year and a 9% organic growth, driven by a robust performance in blood management technologies that saw a 21% revenue increase in the quarter, indicating sustained market demand.
- Margin Changes: The adjusted gross margin for Q4 was 59.7%, down 50 basis points year-over-year, while the full-year gross margin expanded to 60.3%, highlighting the company's efforts in cost control and profitability despite tariff pressures impacting margins.
- Cash Flow Performance: The company generated $45 million in free cash flow in Q4, bringing the total for the year to $210 million with a conversion ratio of 89%, demonstrating significant improvement in cash generation capabilities that will support future investments and shareholder returns.
- Future Outlook: Management expects revenue growth for fiscal 2027 to be between 4% and 7%, with adjusted operating margins projected to improve by 50 to 100 basis points year-over-year, reflecting confidence in future performance despite challenges from tariffs and market fluctuations.
See More
HAEMONETICS CORP - FISCAL 2027 REVENUE GUIDANCE REVEALS 4% - 7% GROWTH - SEC FILING
Fiscal Guidance for 2027: The report outlines the fiscal guidance for the year 2027, indicating a projected revenue growth of 4% to 7%.
Sector Filings: The document highlights the importance of sector filings in relation to the fiscal guidance and revenue projections.
See More
Haemonetics Q4 Earnings Beat Expectations
- Earnings Beat: Haemonetics reported a Q4 non-GAAP EPS of $1.29, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Revenue Growth: The company achieved Q4 revenue of $346 million, a 4.5% year-over-year increase, surpassing analyst expectations by $9.14 million, reflecting its competitive position and sustained product demand in the market.
- Positive Market Reaction: The earnings beat has bolstered investor confidence in Haemonetics, which is expected to drive the stock price up in the short term, enhancing its market valuation.
- Optimistic Outlook: With ongoing product line optimization and strategic market initiatives, Haemonetics is poised for steady growth in the coming quarters, further solidifying its leadership position in the medical device industry.
See More
Haemonetics Set to Announce Q4 Earnings on May 7
- Earnings Announcement: Haemonetics (HAE) is set to release its Q4 earnings on May 7 before market open, with a consensus EPS estimate of $1.27, reflecting a 2.4% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The consensus revenue estimate stands at $336.86 million, up 1.8% year-over-year, suggesting sustained demand in the blood management and plasma markets, which may further enhance its market share.
- Historical Performance: Over the past two years, HAE has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's reliability in financial forecasting and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 9 downward revisions, while revenue estimates experienced 6 upward and 5 downward revisions, indicating market divergence and uncertainty regarding the company's future performance.
See More
Q1 Earnings Review of Medical Devices Sector
- Sector Performance: The medical devices sector saw its seven tracked companies collectively exceed analysts' revenue expectations by 5.2% in Q1, demonstrating resilience despite pricing pressures and regulatory challenges.
- Haemonetics Strong Results: Haemonetics reported revenues of $346.4 million, up 4.8% year-on-year, exceeding analysts' expectations by 2.6%, with its stock rising 10.6% since the report, indicating strong market confidence in its performance.
- STAAR Surgical Rapid Growth: STAAR Surgical achieved revenues of $93.52 million, a remarkable 120% increase year-on-year, outperforming analysts' expectations by 20.8%, with its stock up 14.8%, reflecting its strong market position and growth potential.
- Inspire Medical Systems Struggles: Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year-on-year, exceeding expectations by 1.9%, but its full-year guidance missed expectations, leading to a 19.5% drop in stock price, highlighting market concerns about its future performance.
See More
BofA Upgrades Haemonetics to Buy Amid Conservative FY27 Outlook
- Rating Upgrade: Bank of America upgraded Haemonetics from Neutral to Buy, with analyst Travis Steed noting that while the company has issued a conservative outlook for fiscal 2027, there is likely upside as the year progresses.
- Financial Outlook: Haemonetics projects FY27 revenue between $1.387 billion and $1.427 billion, aligning closely with the FactSet consensus of $1.39 billion, indicating the company's stability and foresight in the market.
- Market Performance: Despite U.S. plasma collections growing in high single-digit percentages in Q4 FY26, the company's outlook suggests only 0% to 2% growth, reflecting a cautious market sentiment regarding its growth potential.
- Valuation Analysis: With a P/E ratio of 11x, Haemonetics trades below what analysts consider fair value, prompting Steed to raise his price target from $70 to $80, based on a 14x multiple for 2027E, highlighting its strong profitability and free cash flow.
See More
Haemonetics Q4 Fiscal 2026 Earnings Call Insights
- Revenue Growth: Haemonetics reported fourth-quarter revenue of $346 million for fiscal 2026, reflecting a 5% increase year-over-year and a 9% organic growth, driven by a robust performance in blood management technologies that saw a 21% revenue increase in the quarter, indicating sustained market demand.
- Margin Changes: The adjusted gross margin for Q4 was 59.7%, down 50 basis points year-over-year, while the full-year gross margin expanded to 60.3%, highlighting the company's efforts in cost control and profitability despite tariff pressures impacting margins.
- Cash Flow Performance: The company generated $45 million in free cash flow in Q4, bringing the total for the year to $210 million with a conversion ratio of 89%, demonstrating significant improvement in cash generation capabilities that will support future investments and shareholder returns.
- Future Outlook: Management expects revenue growth for fiscal 2027 to be between 4% and 7%, with adjusted operating margins projected to improve by 50 to 100 basis points year-over-year, reflecting confidence in future performance despite challenges from tariffs and market fluctuations.
See More
HAEMONETICS CORP - FISCAL 2027 REVENUE GUIDANCE REVEALS 4% - 7% GROWTH - SEC FILING
Fiscal Guidance for 2027: The report outlines the fiscal guidance for the year 2027, indicating a projected revenue growth of 4% to 7%.
Sector Filings: The document highlights the importance of sector filings in relation to the fiscal guidance and revenue projections.
See More
Haemonetics Q4 Earnings Beat Expectations
- Earnings Beat: Haemonetics reported a Q4 non-GAAP EPS of $1.29, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Revenue Growth: The company achieved Q4 revenue of $346 million, a 4.5% year-over-year increase, surpassing analyst expectations by $9.14 million, reflecting its competitive position and sustained product demand in the market.
- Positive Market Reaction: The earnings beat has bolstered investor confidence in Haemonetics, which is expected to drive the stock price up in the short term, enhancing its market valuation.
- Optimistic Outlook: With ongoing product line optimization and strategic market initiatives, Haemonetics is poised for steady growth in the coming quarters, further solidifying its leadership position in the medical device industry.
See More
Haemonetics Set to Announce Q4 Earnings on May 7
- Earnings Announcement: Haemonetics (HAE) is set to release its Q4 earnings on May 7 before market open, with a consensus EPS estimate of $1.27, reflecting a 2.4% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The consensus revenue estimate stands at $336.86 million, up 1.8% year-over-year, suggesting sustained demand in the blood management and plasma markets, which may further enhance its market share.
- Historical Performance: Over the past two years, HAE has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's reliability in financial forecasting and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 2 upward revisions and 9 downward revisions, while revenue estimates experienced 6 upward and 5 downward revisions, indicating market divergence and uncertainty regarding the company's future performance.
See More
